First Patient Dosed in Ph 1 Trial of SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML
“Launching the Phase 1 clinical trial of SENTI-202 marks an important step forward in our mission to redefine the standard of care for patients with AML, offering hope where options are scarce and outcomes are dire. By systematically engineering SENTI-202 to address the complexities of AML heterogeneity while safeguarding healthy marrow cells, we aim to address the critical limitations of existing therapies,” said Kanya Rajangam, MD, PhD, Head of Research & Development and Chief Medical Officer of Senti Bio. “This milestone underscores our unwavering commitment to advancing our clinical program for the betterment of patients, and we eagerly anticipate the potential impact SENTI-202 may have in transforming the lives of people with cancer.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.